Swiss company to produce Russian Sputnik coronavirus vaccine in Italy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

The Russian Direct Investment Fund (RDIF) is set to cooperate with Swiss-based Adienne Pharma & Biotech for Sputnik V coronavirus vaccine production in Italy, chief executive of RDIF Kirill Dmitriev said.

“We are holding talks with the government of Italy. There are many regions enthusiastic in respect of the Sputnik V, which want to produce it domestically. We for the first time cooperate now with the Swiss company Adienne Pharma & Biotech in Sputnik V production in Italy,” Dmitriev said in an interview with the Italian TV Channel Rai 3, as reported by Tass.

The manufacturing mechanism will help to create new jobs and provide Italy with the opportunity to control the product.

Tass reported that the production of the Sputnik V in Italy may start as early as in June. RDIF will announce 20 cooperation projects in ten countries, including Italy, by the end of this march, the chief executive said.

In particular, the Fund is discussing cooperation with Germany and France now.

According to The Hill, Sputnik V, which has a reported efficacy rate of 92 percent for preventing COVID-19 infections, is a two-dose vaccine with lower cold storage requirements than those produced by Pfizer and Moderna.

It has been authorized for emergency use in at least 20 countries.

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back